MedTrace Logo

Use of 99mTc Tilmanocept for Imaging Arterial Inflammation

NCT02542371 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-04-06

No results posted yet for this study

Summary

The purpose of this study is to measure arterial 99mTc-Tilmanocept uptake using single photon emission computed tomography (SPECT/CT) scanning in HIV infected subjects known to have subclinical coronary atherosclerosis as assessed by contrast-enhanced coronary computed tomography angiography (CCTA).

Conditions

Interventions

OTHER

Arterial Imaging

Sponsors & Collaborators

  • Navidea Biopharmaceuticals

    collaborator INDUSTRY

  • Havard University Center for AIDS Research

    collaborator UNKNOWN

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Steven Grinspoon, M.D. · Massachusetts General Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2021-08-31
Completion
2021-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02542371 on ClinicalTrials.gov